Circassia Announces European Launch of NIOX VERO® Nasal Mode for Screening of Primary Ciliary Dyskinesia

Oxford, UK – 12 September 2017: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the European launch of the NIOX VERO® nasal application for the screening of primary ciliary dyskinesia (PCD).  Circassia launched the application at the world’s largest meeting of respiratory professionals, the European Respiratory Society (ERS) 2017 International Congress in Milan, Italy.

At the ERS conference, Circassia hosted a NIOX® workshop at which opinion leaders presented the use of nitric oxide as a biomarker in the diagnosis and management of respiratory diseases.  The presentations focused on the clinical use of fractional exhaled nitric oxide (FeNO) in asthma and the role of nasal nitric oxide (nNO) in diagnosing PCD.  Circassia also hosted an exhibition booth at the conference, demonstrating the use of NIOX VERO® in both these applications.  In addition, Circassia presented data from its recently completed study comparing nNO levels of known PCD subjects with healthy subjects.  This study, which enrolled approximately 160 subjects, demonstrated the ability of NIOX VERO® to differentiate between the two groups.  Following the completion of the study in H2 2016, Circassia finalised nNO measurement software for the NIOX VERO® and associated nasal sampling kits, and recently completed the European certification for this new application.


Steve Harris, Circassia’s CEO, said: “We are delighted to launch the new nasal application for NIOX VERO® to help European specialists diagnose primary ciliary dyskinesia.  This life-long condition can lead to permanent lung damage and early diagnosis and treatment is important.  However, diagnosis can be difficult currently, and we look forward to helping physicians improve the process for patients with this challenging condition.”

For more information please see Circassia's full press release below


More within